HBP.TO - Helix BioPharma Corp.

Toronto - Toronto Delayed Price. Currency in CAD
0.80
0.00 (0.00%)
At close: 11:33AM EDT
Stock chart is not supported by your current browser
Previous Close0.80
Open0.80
Bid0.76 x 0
Ask0.85 x 0
Day's Range0.80 - 0.80
52 Week Range0.70 - 1.10
Volume588
Avg. Volume1,165
Market Cap81.581M
Beta-0.18
PE Ratio (TTM)N/A
EPS (TTM)-0.09
Earnings DateJun 11, 2018 - Jun 15, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire7 days ago

    Helix BioPharma Corp. Closes Private Placement

    Helix BioPharma Corp. (HBP.TO) (HBP.F) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has closed a private placement financing for gross proceeds of CAD1,000,200. Each unit is comprised of one common share and one common share purchase warrant. Each common share purchase warrant will entitle the holder to purchase one common share at an exercise price of $1.50 and have an expiry of five years from the date of issuance.  Helix intends to use the net proceeds of the private placement for working capital and research and development activities.

  • GlobeNewswirelast month

    Helix BioPharma Corp. Announces Fiscal Third Quarter 2018 Results

    RICHMOND HILL, Ontario, June 12, 2018-- Helix BioPharma Corp., a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, announces its financial ...

  • GlobeNewswirelast month

    Helix BioPharma Corp. Closes Private Placement

    Helix BioPharma Corp. (HBP.TO) FSE:HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has closed a private placement financing for gross proceeds of CAD940,800. Each unit is comprised of one common share and one common share purchase warrant. Each common share purchase warrant will entitle the holder to purchase one common share at an exercise price of $1.50 and have an expiry of five years from the date of issuance.  Helix intends to use the net proceeds of the private placement for working capital and research and development activities.

  • GlobeNewswire2 months ago

    Helix BioPharma Corp. Completes Third Dosing Cohort and Initiates Enrollment of the Next Cohort in U.S. Combination Treatment Study of Its Lung Cancer Drug Candidate L-DOS47

    Helix BioPharma Corp. (HBP.TO) (HBP.F) ("Helix" or the "Company"), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that the Safety Review Committee ("SRC") reviewed safety data from the third dosing cohort of the Company’s LDOS001 study and recommended that Helix begin enrollment of patients into the fourth dosing cohort. “We are very encouraged that L-DOS47 in combination with chemotherapeutics continues to be safe and well tolerated by patients,” said Heman Chao, Helix's Chief Executive Officer.  “We look forward to completing this trial under an FDA approved amendment to accelerate dose escalation for this trial”. Eight additional patients to complete the study if no dose limiting toxicity is observed or cohort expansion is required due to safety concern.

  • GlobeNewswire3 months ago

    Helix BioPharma Corp. Closes Private Placement

    Helix BioPharma Corp. (HBP.TO) (HBP.F) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has closed a private placement financing for gross proceeds of CAD605,400. Each unit is comprised of one common share and one common share purchase warrant. Each common share purchase warrant will entitle the holder to purchase one common share at an exercise price of $1.50 and have an expiry of five years from the date of issuance.  Helix intends to use the net proceeds of the private placement for working capital and research and development activities.

  • ACCESSWIRE5 months ago

    Today’s Research Reports on Aphria, Centric Health, Helix BioPharma and TearLab

    NEW YORK, NY / ACCESSWIRE / February 23, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register ...

  • Marketwired5 months ago

    Helix Biopharma Corp. and Helix Immuno-Oncology to Present at the AACR Annual Meeting 2018 in Chicago

    Helix BioPharma Corp. , a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, is pleased to announce that together with its...

  • Marketwired6 months ago

    Helix Biopharma Corp. to Present at the Biotech Showcase Conference

    Helix BioPharma Corp.  , an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has been selected to present at the...

  • Marketwired6 months ago

    Helix Biopharma Corp. Signs Binding Letter of Intent for Development of New CAR-T Technologies

    Helix BioPharma Corp. , an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced the finalization of a collaborative binding...

  • Marketwired7 months ago

    Helix BioPharma Corp. Closes Private Placement

    Helix BioPharma Corp. , an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has closed a private placement financing for...

  • Marketwired7 months ago

    Helix BioPharma Corp. Announces Fiscal First Quarter 2018 Results

    Helix BioPharma Corp. , an immuno-oncology company developing drug candidates for the prevention and treatment of cancer, today announced its financial results for the first quarter of fiscal 2018 ending ...

  • Marketwired7 months ago

    Helix BioPharma Corp. Announces Voting Results From Annual and Special Meeting of Shareholders

    Helix BioPharma Corp. , an immuno-oncology company developing drug candidates for the prevention and treatment of cancer, announced today the results of matters voted on at its annual and special meeting ...

  • Marketwired7 months ago

    Helix BioPharma Corp. Announces Management Change

    Helix BioPharma Corp. , an immuno-oncology company developing drug candidates for the prevention and treatment of cancer, today announced Steve Demas, its Chief Operating Officer, has resigned due to personal ...

  • Marketwired9 months ago

    Helix BioPharma Corp. Announces Fiscal 2017 Year-End Results and Provides Research and Development Program Update

    Helix BioPharma Corp. , an immuno-oncology company developing drug candidates for the prevention and treatment of cancer, today announced its financial results for the year ended July 31, 2017 and an update ...

  • Marketwired9 months ago

    Helix BioPharma Corp. Closes Private Placement

    Helix BioPharma Corp. , an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has closed a private placement financing for...

  • ACCESSWIRE9 months ago

    Today's Research Reports on Advanced Proteome Therapeutics, Cronos Group, Medicure and Helix BioPharma

    NEW YORK, NY / ACCESSWIRE / October 4, 2017 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register ...